Estados financieros detallados de Sana Biotechnology, Inc. (SANA): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $2.92, SANA presenta beneficios negativos (P/E no significativo) y un ROE del -134.49%. La capitalización bursátil es de $813M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1000 | $3.9M | $10.2M | 0 | 0 | 0 | 0 | $12.8M |
| Beneficio Bruto | -$1000 | -$3.9M | -$10.2M | 0 | 0 | 0 | 0 | -$12.8M |
| I+D | $4.0M | $119.4M | $122.7M | $306.5M | $201.0M | $219.8M | $208.7M | $132.0M |
| Generales y Administrativos | $4.2M | $21.8M | $28.3M | $50.4M | $71.6M | $73.3M | $64.0M | $44.3M |
| Gastos Operativos | $8.2M | $141.2M | $151.0M | $356.9M | $272.6M | $293.1M | $272.7M | $178.2M |
| Beneficio Operativo | -$8.2M | -$141.2M | -$161.1M | -$356.9M | -$272.6M | -$293.1M | -$272.7M | -$191.0M |
| EBITDA | -$13.2M | -$138.9M | -$287.0M | -$344.9M | -$253.9M | -$258.7M | -$249.4M | -$231.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$13.2M | -$138.3M | -$297.2M | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Impuestos | 0 | -$7.5M | -$11.9M | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$13.2M | -$130.8M | -$285.3M | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| BPA | $-0.07 | $-0.70 | $-1.63 | $-2.14 | $-1.43 | $-1.46 | $-1.16 | $-0.96 |
| BPA Diluido | $-0.07 | $-0.70 | $-1.63 | $-2.14 | $-1.43 | $-1.46 | $-1.16 | $-0.96 |
| Acciones en Circulación (Diluidas) | $187.3M | $187.3M | $187.5M | $166.4M | $188.3M | $194.5M | $230.9M | $253.2M |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $30.6M | $80.0M | $124.8M | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
| Inversiones a Corto | 0 | $59.0M | $253.5M | $298.0M | $247.2M | $71.7M | $24.9M | $66.5M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $32.6M | $144.3M | $384.5M | $558.1M | $444.4M | $213.5M | $160.8M | $148.7M |
| Inmovilizado Material | $585000 | $68.8M | $109.9M | $161.8M | $159.4M | $145.6M | $135.3M | $65.2M |
| Fondo de Comercio | 0 | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M | $140.6M |
| Activos Intangibles | 0 | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M | $59.2M |
| Activos Totales | $34.3M | $415.2M | $730.3M | $1.13B | $822.7M | $565.3M | $501.0M | $416.9M |
| Cuentas por Pagar | $289000 | 0 | $2.3M | $2.2M | $2.9M | $4.1M | $5.2M | $1.7M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.8M | $19.3M | $31.5M | $99.2M | $111.5M | $64.5M | $45.4M | $78.7M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $47.5M | $557.7M | $1.15B | $400.9M | $323.4M | $277.8M | $250.5M | $256.0M |
| Reservas | -$13.2M | -$144.1M | -$429.4M | -$785.4M | -$1.05B | -$1.34B | -$1.60B | -$1.85B |
| Patrimonio Neto | -$13.2M | -$142.5M | -$421.2M | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M |
| Deuda Total | 0 | $47.7M | $71.9M | $110.9M | $108.3M | $104.1M | $94.2M | $78.9M |
| Deuda Neta | -$30.6M | -$91.3M | -$306.4M | -$440.1M | -$315.7M | -$101.1M | -$58.3M | -$59.5M |
| Capital Circulante | $30.8M | $124.9M | $353.0M | $458.9M | $332.9M | $149.0M | $115.4M | $70.0M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$13.2M | -$130.8M | -$285.3M | -$355.9M | -$269.5M | -$283.3M | -$266.8M | -$244.2M |
| Amortizaciones | $1000 | $1.8M | $5.9M | $11.1M | $15.6M | $24.6M | $15.5M | $12.8M |
| Compensación en Acciones | $118000 | $1.5M | $5.8M | $22.4M | $38.3M | $35.5M | $37.7M | $25.5M |
| Cambio en Capital Circulante | -$308000 | $10.5M | $6.2M | $9.8M | $7.5M | $18.6M | -$1.2M | -$10.1M |
| Flujo de Caja Operativo | -$13.5M | -$85.5M | -$138.0M | -$251.1M | -$290.1M | -$253.6M | -$223.2M | -$143.8M |
| Inversiones (CapEx) | -$460000 | -$26.2M | -$23.9M | -$29.9M | -$20.9M | -$20.0M | -$33.4M | -$938000 |
| Adquisiciones | 0 | -$3.2M | 0 | 0 | -$231438 | -$192044 | 0 | $1.4M |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$14.0M | -$111.7M | -$161.9M | -$280.9M | -$310.9M | -$273.6M | -$256.6M | -$144.8M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -887.2% | -118.2% | -24.8% | +24.3% | -5.1% | +5.8% | +8.5% | |
| Crecimiento BPA (anual) | -890.1% | -132.9% | -31.3% | +33.2% | -2.1% | +20.5% | +17.2% | |
| Cambio en Acciones (anual) | +0.0% | +0.1% | -11.2% | +13.2% | +3.3% | +18.7% | +9.7% | |
| Crecimiento FCF (anual) | -700.3% | -44.9% | -73.6% | -10.7% | +12.0% | +6.2% | +43.6% | |
| Tasa Impositiva Efectiva | -0.0% | 5.5% | 4.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.07 | $-0.60 | $-0.86 | $-1.69 | $-1.65 | $-1.41 | $-1.11 | $-0.57 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $187.3M | $187.3M | $187.5M | $166.4M | $188.3M | $194.5M | $230.9M | $253.2M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -134.49% |
| Rentabilidad sobre capital invertido | -64.54% |
| Rentabilidad sobre activos | -49.09% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.48 |
| Ratio corriente | 1.38 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -5.10 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -496.46 | -50.14 | -21.53 | -7.23 | -2.76 | -2.79 | -1.41 | -4.24 |
| P/VC | -498.61 | -46.13 | -15.63 | 3.54 | 1.49 | 2.76 | 1.50 | 6.41 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: DNTH · INBX · KOD · NKTR · NRIX · OCS · PHAT
Explorar sector: Healthcare · Biotechnology
Más secciones de SANA: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones